Pages that link to "Q45287928"
Jump to navigation
Jump to search
The following pages link to Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer (Q45287928):
Displayed 50 items.
- The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy (Q21284978) (← links)
- Trastuzumab containing regimens for early breast cancer (Q24200192) (← links)
- Preoperative chemotherapy for women with operable breast cancer (Q24245281) (← links)
- Activity of the kinesin spindle protein inhibitor ispinesib (SB-715992) in models of breast cancer (Q24615262) (← links)
- High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller (Q24641848) (← links)
- A clinician's guide to biosimilars in oncology (Q26748410) (← links)
- Brain metastasis in human epidermal growth factor receptor 2-positive breast cancer: from biology to treatment (Q26751008) (← links)
- Infracentimetric HER-2 positive breast tumours-review of the literature (Q26774597) (← links)
- Clinical implications of the intrinsic molecular subtypes of breast cancer (Q26800996) (← links)
- Validation of proposed prostate cancer biomarkers with gene expression data: a long road to travel (Q27001399) (← links)
- Neoadjuvant therapy of early stage human epidermal growth factor receptor 2 positive breast cancer: latest evidence and clinical implications (Q27001729) (← links)
- Neoadjuvant therapy in the treatment of breast cancer (Q27694514) (← links)
- Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer (Q28072513) (← links)
- The genomics and therapeutics of HER2-positive gastric cancer-from trastuzumab and beyond (Q28078788) (← links)
- Treatment of early-stage HER2+ breast cancer-an evolving field (Q28081124) (← links)
- Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer (Q28240692) (← links)
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial (Q28254919) (← links)
- Ulinastatin reduces the resistance of liver cancer cells to epirubicin by inhibiting autophagy (Q28545086) (← links)
- Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2 (Q29620608) (← links)
- Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. (Q30249335) (← links)
- Translating neoadjuvant therapy into survival benefits: one size does not fit all. (Q30251738) (← links)
- Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma (Q30411769) (← links)
- Analysis of neoadjuvant therapies in breast cancer with respect to pathological complete response, disease-free survival and overall survival: 15 years follow-up data from Kuwait (Q30661022) (← links)
- Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials. (Q30857631) (← links)
- Paclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancer (Q33407805) (← links)
- A phase II trial of dose-dense (biweekly) paclitaxel plus carboplatin as neoadjuvant chemotherapy for operable breast cancer. (Q33430463) (← links)
- Usefulness of miRNA profiles for predicting pathological responses to neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer (Q33599465) (← links)
- Pertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations (Q33680109) (← links)
- Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab (Q33680890) (← links)
- Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment (Q33698446) (← links)
- Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes (Q33712925) (← links)
- Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study (Q33739253) (← links)
- Filling in the gaps: reporting of concurrent supportive care therapies in breast cancer chemotherapy trials. (Q33785011) (← links)
- Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer (Q33813431) (← links)
- Differential impact of hormone receptor status on survival and recurrence for HER2 receptor-positive breast cancers treated with Trastuzumab (Q33843810) (← links)
- Recurrent prostate cancer genomic alterations predict response to brachytherapy treatment (Q33852664) (← links)
- Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors (Q33949465) (← links)
- Dual HER2-targeting without chemotherapy and estrogen deprivation in the neoadjuvant setting (Q33973172) (← links)
- Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions (Q34023704) (← links)
- Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center (Q34032803) (← links)
- Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy. (Q34059719) (← links)
- Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma (Q34064466) (← links)
- The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy (Q34075789) (← links)
- Circulating tumor cells in breast cancer. (Q34077349) (← links)
- Adjuvant and Neoadjuvant Therapy with Lapatinib in ErbB2-Overexpressing Breast Cancer (Q34095759) (← links)
- Future Roles of Lapatinib in ErbB2-Positive Breast Cancer: Adjuvant and Neoadjuvant Trials (Q34096246) (← links)
- Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based study (Q34129444) (← links)
- NEO adjuvant chemotherapy in breast cancer: What have we learned so far? (Q34138174) (← links)
- Targeting HER2 in breast cancer: overview of long-term experience (Q34272044) (← links)
- Present and future evolution of advanced breast cancer therapy (Q34274925) (← links)